All University Medical Center Hamburg-Eppendorf articles
-
NewsIs the licensed Zaire ebolavirus vaccine suitable to combat the current Bundibugyo ebolavirus outbreak?
Researchers provide evidence of possible cross-protection through an already licensed Zaire ebolavirus vaccine.
-
NewsLong-term cure rates for multidrug-resistant tuberculosis much better than expected
A new national cohort study from Latvia provides important insights into the treatment of multidrug-resistant tuberculosis (MDR-TB). The study shows that long-term disease-free survival rates are significantly higher than previous standard indicators suggest.
-
NewsPreparedness for future pandemics: MERS vaccine candidate shows long-lasting immune response
A new study has shown for the first time that an experimental vaccine against Middle East Respiratory Syndrome (MERS) induces a stable and functional immune response in humans that persists for at least two years after a booster vaccination.
-
NewsMERS coronavirus vaccine tested as safe and effective in phase Ib clinical trial
The safety, immunogenicity and optimal dosing regimen of the MVA-MERS-S vaccine candidate have been investigated in a phase Ib study in healthy individuals who were previously infected with SARS-CoV-2.
-
NewsNeutralizing antibodies target resistant bacteria
Scientists have discovered antibodies that could lead to a highly potent treatment option of acute and chronic infections with Pseudomonas aeruginosa.
-
NewsMonoclonal antibody shows promise for treating chronic hepatitis B and D infections
In a preclinical study, the potential of an engineered investigational human monoclonal antibody for the treatment of chronic hepatitis B and hepatitis D has been demonstrated.
-
NewsStudy outlines world’s third successful cure of HIV infection after stem cell transplantation
The ‘Düsseldorf patient’, a 53-year-old man, is now the third person in the world to be completely cured of HIV with a stem cell transplant.